Pharmacokinetic, pharmacodynamic and phase II study of gefitinib in patients with malignant pleural effusion from non-small cell lung cancer

Pharmacokinetic, pharmacodynamic and phase II study of gefitinib in patients with malignant pleural effusion from non-small cell lung cancer - Pharmacokinetic, pharmacodynamic and phase II study of gefitinib in patients with malignant pleural effusion from non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002953

Enrollment

Registered

2009-12-28

Start date

2006-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Oral gefitinib treatment Chest tube drainage and sampling pleural effusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmed non-small cell lung cancer 2) Requirement of chest tube drainage for symptomatic relief from pathologically confirmed malignant pleural effusion. 3) Measurable or evaluable disease 4) Performance status (ECOG): 0-3. 5) Adequate major organ functions 6) Written informed consent

Exclusion criteria

Exclusion criteria: 1) Comorbidity of interstitial lung disease, severe pneumoconiosis, or severe chronic obstructive lung diseases. 2) Other uncontrolled comorbid diseases.

Design outcomes

Primary

Measure	Time frame
Efficacy and safety Pharmacokinetics Pharmacodynamics	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026